母源性抗PfSEA-1抗体对子代内源性抗体产生的影响
在630名坦桑尼亚婴儿中随访至24月龄,评估母源性抗PfSEA-1A抗体是否干扰婴儿自然暴露后抗PfSEA-1A抗体的产生。结果显示母婴抗体不削弱疟原虫血症驱动的婴儿抗体应答,提示母体接种PfSEA-1A疫苗不太可能干扰婴儿自然免疫应答。
要点
- 出生后6个月内疟原虫血症婴儿在6和12月龄时抗PfSEA-1A抗体显著更高。
- 脐血母源性抗PfSEA-1A抗体显著修饰这一效应。
- 母体接种PfSEA-1A疫苗不太可能干扰婴儿自然免疫应答。
核心结论
- 母体接种PfSEA-1A疫苗不太可能干扰婴儿期暴露后自然获得的抗PfSEA-1A免疫应答。
研究设计与样本
- 随访630名坦桑尼亚婴儿,在出生及6、12、18、24月龄检测抗PfSEA-1A抗体(aa 810-1023;PfSEA-1A)。
主要发现
- 出生后6个月内发生疟原虫血症的婴儿在6和12月龄时抗PfSEA-1A抗体显著高于未感染婴儿。
- 脐血母源性抗PfSEA-1A抗体显著修饰上述效应。
- 出生后6个月内,脐血母源性抗体水平低者的婴儿抗PfSEA-1A抗体与疟原虫暴露显著相关,中、高水平者仅为边缘显著相关。
- 出生后6个月内,脐血母源性抗PfSEA-1A抗体未消除疟原虫血症驱动的婴儿抗PfSEA-1A抗体发展。
临床怎么用
- 支持进一步评估PfSEA-1A作为母体疫苗候选,无需担忧其抑制婴儿自然抗体应答。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We evaluated whether maternally-derived antibodies to a malarial vaccine candidate, Plasmodium falciparum Schizont Egress Antigen-1 (PfSEA-1), in cord blood interfered with the development of infant anti-PfSEA-1 antibodies in response to natural exposure. METHODS: We followed 630 Tanzanian infants who were measured their antibodies against PfSEA-1 (aa 810-1023; PfSEA-1A) at birth and 6, 12, 18, and 24 months of age, and examined the changes in anti-PfSEA-1A antibody levels in response to parasitemia, and evaluated whether maternally-derived anti-PfSEA-1A antibodies in cord blood modified infant anti-PfSEA-1A immune responses. RESULTS: Infants who experienced parasitemia during the first 6 months of life had significantly higher anti-PfSEA-1A antibodies at 6 and 12 months of age compared to uninfected infants. Maternally-derived anti-PfSEA-1A antibodies in cord blood significantly modified this effect during the first 6 months. During this period, infant anti-PfSEA-1A antibody levels were significantly associated with their P. falciparum exposure when they were born with low, but not higher, maternally-derived anti-PfSEA-1A antibody levels in cord blood. Nevertheless, during the first 6 months of life, maternally-derived anti-PfSEA-1A antibodies in cord blood did not abrogate the parasitemia driven development of infant anti-PfSEA-1A: parasitemia were significantly correlated with anti-PfSEA-1A antibody levels at 6 months of age in the infants born with low maternally-derived anti-PfSEA-1A antibody levels in cord blood and borderline significantly correlated in those infants born with middle and high levels. CONCLUSIONS: Maternal vaccination with PfSEA-1A is unlikely to interfere with the development of naturally acquired anti-PfSEA-1A immune responses following exposure during infancy.
引用
- Park S, Nixon CE, Pond-Tor S, et al. Impact of maternally derived antibodies to Plasmodium falciparum Schizont Egress Antigen-1 on the endogenous production of anti-PfSEA-1 in offspring. Vaccine. 2019. PMID: 31288996. doi:10.1016/j.vaccine.2019.06.084
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。